Development of an Analytical Method for Identification of the Genotoxic Impurity of Quetiapine Fumarate by High-Performance Thin-Layer Chromatography

被引:0
作者
Pankaj B. Miniyar
Asha B. Thomas
Resham D. Kulkarni
Supriya A. Kadam
Parminder P. Chouhan
Sohan S. Chitlange
机构
[1] Affiliated to Savitribai Phule Pune University,Sinhgad Technical Education Society’s Sinhgad Institute of Pharmacy
[2] Pune,Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research
[3] Affiliated to Savitribai Phule Pune University,undefined
[4] Pune,undefined
来源
JPC – Journal of Planar Chromatography – Modern TLC | 2019年 / 32卷
关键词
Threshold of toxicological concern; Genotoxic impurity; Active pharmaceutical ingredient; Validation; 2-Chloroaniline;
D O I
暂无
中图分类号
学科分类号
摘要
Genetic mutations, chromosomal breaks, and chromosomal rearrangements, which are induced due to organic impurities, are considered as potential genotoxic impurities. The European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) have set a threshold of toxicological concern (TTC) of 1.5 µg per person per day for each impurity. A sensitive and simple high-performance thin-layer chromatography (HPTLC) method has been developed and validated for determination of the potential genotoxic impurity, namely, 2-chloroaniline, at trace levels in quetiapine fumarate. The method was found to be specific and selective for the application. The limit of detection (LOD) and limit of quantification (LOQ) for quetiapine fumarate were found to be 1.27 and 3.87 ng per band. The LOD and LOQ values for 2-chloroaniline were found 0.018 and 0.054 ng per band, respectively. The calibration curve for 2-chloroaniline was linear over a concentration range from 2.5 to 12.5 ng. The method was found to be specific, precise, linear, and accurate and can be employed for monitoring and estimation of levels of 2-chloroaniline in quetiapine fumarate.
引用
收藏
页码:317 / 321
页数:4
相关论文
共 64 条
[1]  
Reddy AV(2015)undefined J. Sep. Sci. 38 764-769
[2]  
Jaafar J(2010)undefined J. Pharm. Bio. Anal. 51 999-1014
[3]  
Umar K(2002)undefined Clin. Ther. 24 209-222
[4]  
Majid ZA(2010)undefined J. Clin. Res. 4 24-31
[5]  
Gajulapalle M(2010)undefined Thai J. Pharm. Sci. 34 146-154
[6]  
Liu D(2012)undefined Croat. Chem. Acta 85 9-17
[7]  
Sun M(2009)undefined Int. J. Chem. Tech. 1 1153-1161
[8]  
Kord A(2009)undefined Int. J. Chem. Tech. 1 898-904
[9]  
Cutler AJ(2009)undefined Acta Chromatogr. 21 83-93
[10]  
Goldstein JM(2010)undefined Eurasian J. Anal. Chem. 5 246-253